Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Camilla Gare
Camilla Gare
Associate
London +44 20 7067 2292 cgare@cov.com Download V-card

Camilla Gare is a corporate associate based in Covington’s London office.

Ms. Gare advises clients on a broad range of transactional and commercial matters, including, mergers and acquisitions, venture capital, restructurings, private equity, financings, and general corporate advisory work.

Ms. Gare acts for investors and companies at all stages of development across a range of industries. Ms. Gare has particular experience advising on deals in the life sciences and technology sectors, and her practice covers Europe and the Middle East.

  • Advising Merck & Co., Inc. on an ongoing basis on global post-merger integrations of Schering-Plough Corporation and Cubist Pharmaceuticals.
  • Advising BenevolentAI, a global leader in the development and application of AI for scientific innovation, on an £80 million equity investment by new and existing investors, including Woodford Investment Management.
  • Advising BenevolentAI on its acquisition of Proximagen Limited, a Cambridge, UK-based drug discovery and development company.
  • Advising the syndicate of investors, including Touchstone Innovations, Johnson & Johnson Innovation – JJDC, Inc., Cambridge Innovation Capital and Woodford Patient Capital Trust, on both their £31.5 million Series A and £17-27 million Series B investments in Inivata Limited, a clinical cancer genomics company employing the precision of ctDNA analysis to improve personalized healthcare in oncology.
  • Representing AstraZeneca in connection with its entry into a commercialization agreement with Aspen Global Incorporated for rights to its global anesthetics portfolio outside the U.S.
  • Advising Touchstone Innovations on various investments, including portfolio companies ApcinteX, Inivata and Precision Ocular.
  • Advising AstraZeneca on its acquisition of the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones.
  • Acting for the Dubai-based family office of a high net worth individual on the disposal of a minority stake in an African telecommunications company.
  • Advising an LSE-listed industrial services company focused in the energy and natural resources sectors on the refinancing of its principal facilities under a revolving credit facility arranged by a syndicate of leading banks.
  • Advising various international companies across a range of sectors on incorporating subsidiary companies and representative branches within onshore Dubai and in the Dubai Free Zones.

Previous Experience

  • Corporate associate in the Dubai office of an international law firm.